Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20090069247 A1
Publication typeApplication
Application numberUS 11/869,230
Publication dateMar 12, 2009
Filing dateOct 9, 2007
Priority dateOct 6, 2006
Also published asUS8299017, US8796203, US20110136747, US20130102547, WO2008043107A2, WO2008043107A3
Publication number11869230, 869230, US 2009/0069247 A1, US 2009/069247 A1, US 20090069247 A1, US 20090069247A1, US 2009069247 A1, US 2009069247A1, US-A1-20090069247, US-A1-2009069247, US2009/0069247A1, US2009/069247A1, US20090069247 A1, US20090069247A1, US2009069247 A1, US2009069247A1
InventorsBlake Paterson, Amir Tamiz, Niranjan Pandey
Original AssigneeBlake Paterson, Amir Tamiz, Niranjan Pandey
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Use of tight junction antagonists to treat inflammatory bowel disease
US 20090069247 A1
Abstract
The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.
Images(11)
Previous page
Next page
Claims(33)
1. A method of treating inflammatory bowel disease comprising:
administering to a subject in need thereof a composition comprising a tight junction antagonist.
2. A method according to claim 1, wherein the antagonist is a peptide.
3. A method according to claim 2, wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-24.
4. A method according to claim 2, wherein the peptide comprises the sequence
GGVLVQPG. (SEQ ID NO:15)
5. A method according to claim 2, wherein the peptide consists essentially of the sequence
GGVLVQPG. (SEQ ID NO:15)
6. A method according to claim 1, wherein the composition is a delayed release composition.
7. A method according to claim 1, wherein the composition comprises a therapeutic agent.
8. A method according to claim 7, wherein the therapeutic agent includes one or more agents selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics.
9. A method according to claim 7, wherein the therapeutic agent comprises a steroid.
10. A method of treating Crohn's disease comprising:
administering to a subject in need thereof a composition comprising a tight junction antagonist.
11. A method according to claim 10, wherein the antagonist is a peptide.
12. A method according to claim 11, wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-24.
13. A method according to claim 11, wherein the peptide comprises the sequence
GGVLVQPG. (SEQ ID NO:15)
14. A method according to claim 11, wherein the peptide consists essentially of the sequence
GGVLVQPG. (SEQ ID NO:15)
15. A method according to claim 10, wherein the composition is a delayed release composition.
16. A method according to claim 10, wherein the composition comprises a therapeutic agent.
17. A method according to claim 16, wherein the therapeutic agent includes one or more agents selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics.
18. A method according to claim 16, wherein the therapeutic agent comprises a steroid.
19. A method of treating ulcerative colitis comprising:
administering to a subject in need thereof a composition comprising a tight junction antagonist.
20. A method according to claim 19, wherein the antagonist is a peptide.
21. A method according to claim 20, wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1-24.
22. A method according to claim 20, wherein the peptide comprises the sequence
GGVLVQPG. (SEQ ID NO:15)
23. A method according to claim 20, wherein the peptide consists essentially of the sequence
GGVLVQPG. (SEQ ID NO:15)
24. A method according to claim 19, wherein the composition is a delayed release composition.
25. A method according to claim 19, wherein the composition comprises a therapeutic agent.
26. A method according to claim 25, wherein the therapeutic agent includes one or more agents selected from the group consisting of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics.
27. A method according to claim 25, wherein the therapeutic agent comprises a steroid.
28. A method according to claim 1, wherein the subject is a human.
29. A method according to claim 1, wherein the subject is a dog.
30. A method according to claim 10, wherein the subject is a human.
31. A method according to claim 10, wherein the subject is a dog.
32. A method according to claim 19, wherein the subject is a human.
33. A method according to claim 19, wherein the subject is a dog.
Description

In normal bowels, the immune reaction is regulated to maintain homeostasis of the gut. Inflammatory bowel disease (IBD) is a phrase used to describe an inappropriate immune response that occurs in the bowels of affected individuals. Two major types of IBD have been described: Crohn's disease (CD) and ulcerative colitis (UC). Both forms of IBD show abnormal profiles of T cell mediated immunity. In the gut of CD, a strong Th1 reaction is induced, while the Th2 response is upregulated in the colon of UC.

A variety of inflammatory cytokines have been implicated in IBD. For example, in UC increased proinflammatory cytokine production is observed. IL-13 was identified as an important effector cytokine in UC that impairs epithelial barrier function by affecting epithelial apoptosis, tight junctions, and restitution velocity (Heller, et al., Gastroenterology 129(2): 550-64, 2005). TNF-α has been implicated in the pathology of CD and antibodies directed against TNF-α have been used to treat CD (see Nakamura, et al. World J Gastroenterol 2006 August 7; 12(29): 4628-4635).

The barrier function of the intestines is impaired in IBD. For example, Crohn's disease is associated with increased permeability of the intestinal barrier even in quiescent patients (Oshitani, et al., Int J Mol Med 15(3):407-10, 2005). A TNF-α-induced increase in intestinal epithelial tight junction (TJ) permeability has been proposed to be an important proinflammatory mechanism contributing to intestinal inflammation in Crohn's disease and other inflammatory conditions (see Ye et al., American Journal of Physiology-Gastrointestinal and Liver Physiology, 290(3):496-504, 2006). Increased intestinal permeability during episodes of active disease correlates with destruction or rearrangement of the tight junction protein complex (Willemsen, et al. Clin. Exp. Immunol. 142(2): 275-284, 2005).

Zonula occludens toxin (ZOT), which is produced by Vibrio cholerae, has been characterized by Fasano et al., (Proc. Natl. Acad. Sci., USA, 8:5242-5246 (1991)) and the sequence has been determined (GenBank accession no. A43864). ZOT increases the intestinal permeability of rabbit ileal mucosa by modulating the structure of intercellular tight junctions.

Peptide antagonists of tight junction opening were described in U.S. Pat. No. 6,458,925, which is incorporated by reference herein in its entirety, which corresponds to WO 00/07609. Peptide antagonists of tight junction opening may bind to the receptor utilized by the zonnula occludens toxin expressed by Vibrio cholerae, yet not function to physiologically modulate the opening of mammalian tight junctions. The peptide antagonists competitively inhibit the binding of ZOT and zonulin to the ZOT receptor, thereby inhibiting the ability of ZOT and zonulin to physiologically modulate the opening of mammalian tight junctions.

The main treatments available for IBD are steroids and immunosuppressive agents which non-specifically reduce immunity and inflammation. These therapies are prone to undesired side effects. There remains a need in the art for treatments of IBD. This need and others are met by the present invention.

SUMMARY OF THE INVENTION

The present invention provides methods and materials for treating inflammatory bowel disease. In some embodiments, the invention provides methods of treating inflammatory bowel disease comprising administering to a subject in need thereof a composition comprising a tight junction antagonist. As used herein, a “subject” may be any mammal, for example, a human, dog, cat, horse, cow, etc. In some embodiments, a subject may be a human. In other embodiments, a subject may be a dog. Any tight junction antagonist may be used, for example, a tight junction antagonist of the invention may be a peptide. When a tight junction antagonist for use in the invention is a peptide, the peptide may comprise one or more of SEQ ID NOs: 1-24, which may be on the same or different molecules. In some embodiments, a peptide tight junction antagonist may comprise the sequence GGVLVQPG (SEQ ID NO: 15). In some embodiments, the peptide tight junction antagonist may consist essentially of the sequence GGVLVQPG (SEQ ID NO: 15). Compositions suitable for use in treating IBD may be formulated in any manner known to those skilled in the art. In some embodiments, a composition suitable for treating IBD may comprise a tight junction antagonist and may be a delayed release composition. Compositions for use in treating IBD, delayed release or otherwise, may comprise one or more tight junction antagonists and one or more therapeutic agents. Suitable therapeutic agents include, but are not limited to, aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics. In some embodiments, a composition suitable for treating IBD may comprise a peptide tight junction antagonist (e.g., a peptide comprising SEQ ID NO: 15) and a therapeutic agent, e.g., a steroid.

The present invention provides methods and materials for treating Crohn's disease. In some embodiments, the invention provides methods of treating Crohn's disease comprising administering to a subject in need thereof a composition comprising a tight junction antagonist. Any tight junction antagonist may be used, for example, a tight junction antagonist of the invention may be a peptide. When a tight junction antagonist for use in the invention is a peptide, the peptide may comprise one or more of SEQ ID NOs: 1-24, which may be on the same or different molecules. In some embodiments, a peptide tight junction antagonist may comprise the sequence GGVLVQPG (SEQ ID NO:15). In some embodiments, the peptide tight junction antagonist may consist essentially of the sequence GGVLVQPG (SEQ ID NO:15). Compositions suitable for use in treating Crohn's disease may be formulated in any manner known to those skilled in the art. In some embodiments, a composition suitable for treating Crohn's disease may comprise a tight junction antagonist and may be a delayed release composition. Compositions for use in treating Crohn's disease, delayed release or otherwise, may comprise one or more tight junction antagonists and one or more therapeutic agents. Suitable therapeutic agents include, but are not limited to, aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics. In some embodiments, a composition suitable for treating Crohn's disease may comprise a peptide tight junction antagonist (e.g., a peptide comprising SEQ ID NO: 15) and a therapeutic agent, e.g., a steroid.

The present invention provides methods and materials for treating ulcerative colitis. In some embodiments, the invention provides methods of treating ulcerative colitis comprising administering to a subject in need thereof a composition comprising a tight junction antagonist. Any tight junction antagonist may be used, for example, a tight junction antagonist of the invention may be a peptide. When a tight junction antagonist for use in the invention is a peptide, the peptide may comprise one or more of SEQ ID NOs: 1-24, which may be on the same or different molecules. In some embodiments, a peptide tight junction antagonist may comprise the sequence GGVLVQPG (SEQ ID NO:15). In some embodiments, the peptide tight junction antagonist may consist essentially of the sequence GGVLVQPG (SEQ ID NO:15). Compositions suitable for use in treating ulcerative colitis may be formulated in any manner known to those skilled in the art. In some embodiments, a composition suitable for treating ulcerative colitis may comprise a tight junction antagonist and may be a delayed release composition. Compositions for use in treating ulcerative colitis, delayed release or otherwise, may comprise one or more tight junction antagonists and one or more therapeutic agents. Suitable therapeutic agents include, but are not limited to, aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapeutics. In some embodiments, a composition suitable for treating ulcerative colitis may comprise a peptide tight junction antagonist (e.g., a peptide comprising SEQ ID NO: 15) and a therapeutic agent, e.g., a steroid.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows Body Weight area under the curve from 4-17 weeks of age.

FIG. 2 shows a measurement of Gastric Permeability measured as sucrose excretion.

FIG. 3 shows Small Intestinal Permeability measured by lactulose mannitol test.

FIG. 4 shows Small Intestinal Permeability measured by lactulose mannitol test.

FIG. 5 shows in vitro measurement of colonic permeability at 8 weeks of age.

FIG. 6 shows in vitro colonic electrical resistance at 8 weeks of age.

FIG. 7 shows colonic inflammation (neutrophil infiltration) at 17 weeks.

FIG. 8 shows colonic inflammation at 17 weeks (TNF secretion over 24 hours).

FIG. 9 shows colonic inflammation at 17 weeks (IFN secretion over 24 hours).

FIG. 10 shows Colonic Permeability as measured by sucralose excretion.

DETAILED DESCRIPTION OF THE INVENTION

Antagonists of Tight Junction Opening

Any antagonist of tight junction opening may be used in the practice of the present invention. As used herein, tight junction antagonists prevent, inhibit or reduce the opening of tight junctions. A tight junction antagonist may bind to the zonulin receptor and prevent, inhibit, reduce or reverse the tight junction opening triggered by zonulin. For example, antagonists of the invention may comprise peptide antagonists. Examples of peptide antagonists include, but are not limited to, peptides that comprise an amino acid sequence selected from the group consisting of

Gly Arg Val Cys Val Gln Pro Gly, (SEQ ID NO:1)
Gly Arg Val Cys Val Gln Asp Gly, (SEQ ID NO:2)
Gly Arg Val Leu Val Gln Pro Gly, (SEQ ID NO:3)
Gly Arg Val Leu Val Gln Asp Gly, (SEQ ID NO:4)
Gly Arg Leu Cys Val Gln Pro Gly, (SEQ ID NO:5)
Gly Arg Leu Cys Val Gln Asp Gly, (SEQ ID NO:6)
Gly Arg Leu Leu Val Gln Pro Gly, (SEQ ID NO:7)
Gly Arg Leu Leu Val Gln Asp Gly, (SEQ ID NO:8)
Gly Arg Gly Cys Val Gln Pro Gly, (SEQ ID NO:9)
Gly Arg Gly Cys Val Gln Asp Gly, (SEQ ID NO:10)
Gly Arg Gly Leu Val Gln Pro Gly, (SEQ ID NO:11)
Gly Arg Gly Leu Val Gln Asp Gly, (SEQ ID NO:12)
Gly Gly Val Cys Val Gln Pro Gly, (SEQ ID NO:13)
Gly Gly Val Cys Val Gln Asp Gly, (SEQ ID NO:14)
Gly Gly Val Leu Val Gln Pro Gly, (SEQ ID NO:15)
Gly Gly Val Leu Val Gln Asp Gly, (SEQ ID NO:16)
Gly Gly Leu Cys Val Gln Pro Gly, (SEQ ID NO:17)
Gly Gly Leu Cys Val Gln Asp Gly, (SEQ ID NO:18)
Gly Gly Leu Leu Val Gln Pro Gly, (SEQ ID NO:19)
Gly Gly Leu Leu Val Gln Asp Gly, (SEQ ID NO:20)
Gly Gly Gly Cys Val Gln Pro Gly, (SEQ ID NO:21)
Gly Gly Gly Cys Val Gln Asp Gly, (SEQ ID NO:22)
Gly Gly Gly Leu Val Gln Pro Gly, (SEQ ID NO:23)
and
Gly Gly Gly Leu Val Gln Asp Gly, (SEQ ID NO:24)

When the antagonist is a peptide, any length of peptide may be used. Generally, the size of the peptide antagonist will range from about 6 to about 100, from about 6 to about 90, from about 6 to about 80, from about 6 to about 70, from about 6 to about 60, from about 6 to about 50, from about 6 to about 40, from about 6 to about 30, from about 6 to about 25, from about 6 to about 20, from about 6 to about 15, from about 6 to about 14, from about 6 to about 13, from about 6 to about 12, from about 6 to about 11, from about 6 to about 10, from about 6 to about 9, or from about 6 to about 8 amino acids in length. Peptide antagonists of the invention may be from about 8 to about 100, from about 8 to about 90, from about 8 to about 80, from about 8 to about 70, from about 8 to about 60, from about 8 to about 50, from about 8 to about 40, from about 8 to about 30, from about 8 to about 25, from about 8 to about 20, from about 8 to about 15, from about 8 to about 14, from about 8 to about 13, from about 8 to about 12, from about 8 to about 11, or from about 8 to about 10 amino acids in length. Peptide antagonists of the invention may be from about 10 to about 100, from about 10 to about 90, from about 10 to about 80, from about 10 to about 70, from about 10 to about 60, from about 10 to about 50, from about 10 to about 40, from about 10 to about 30, from about 10 to about 25, from about 10 to about 20, from about 10 to about 15, from about 10 to about 14, from about 10 to about 13, or from about 10 to about 12 amino acids in length. Peptide antagonists of the invention may be from about 12 to about 100, from about 12 to about 90, from about 12 to about 80, from about 12 to about 70, from about 12 to about 60, from about 12 to about 50, from about 12 to about 40, from about 12 to about 30, from about 12 to about 25, from about 12 to about 20, from about 12 to about 15, or from about 12 to about 14 amino acids in length. Peptide antagonists of the invention may be from about 15 to about 100, from about 15 to about 90, from about 15 to about 80, from about 15 to about 70, from about 15 to about 60, from about 15 to about 50, from about 15 to about 40, from about 15 to about 30, from about 15 to about 25, from about 15 to about 20, from about 19 to about 15, from about 15 to about 18, or from about 17 to about 15 amino acids in length.

The peptide antagonists can be chemically synthesized and purified using well-known techniques, such as described in High Performance Liquid Chromatography of Peptides and Proteins: Separation Analysis and Conformation, Eds. Mant et al., C.R.C. Press (1991), and a peptide synthesizer, such as Symphony (Protein Technologies, Inc); or by using recombinant DNA techniques, i.e., where the nucleotide sequence encoding the peptide is inserted in an appropriate expression vector, e.g., an E. coli or yeast expression vector, expressed in the respective host cell, and purified therefrom using well-known techniques.

Formulations

The compositions of the invention may be formulated for enteric delivery, for example, may comprise one or more coatings, for example, delayed release coating containing one or more enteric agents. A delayed release coating is typically substantially stable in gastric fluid and substantially unstable (e.g., dissolves rapidly or is physically unstable) in intestinal fluid, thus providing for substantial release of the tight junction antagonist from the composition in the duodenum or the jejunum. Typically, compositions comprising a tight junction antagonist (e.g., peptide antagonist) comprise a pharmaceutically effective amount of the antagonist. The pharmaceutically effective amount of antagonist (e.g., peptide antagonist) employed may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.

Compositions of the invention may comprise one or more tight junction antagonists at a level of from about 0.1 wt % to about 20 wt %, from about 0.1 wt % to about 18 wt %, from about 0.1 wt % to about 16 wt %, from about 0.1 wt % to about 14 wt %, from about 0.1 wt % to about 12 wt %, from about 0.1 wt % to about 10 wt %, from about 0.1 wt % to about 8 wt %, from about 0.1 wt % to about 6 wt %, from about 0.1 wt % to about 4 wt %, from about 0.1 wt % to about 2 wt %, from about 0.1 wt % to about 1 wt %, from about 0.1 wt % to about 0.9 wt %, from about 0.1 wt % to about 0.8 wt %, from about 0.1 wt % to about 0.7 wt %, from about 0.1 wt % to about 0.6 wt %, from about 0.1 wt % to about 0.5 wt %, from about 0.1 wt % to about 0.4 wt %, from about 0.1 wt % to about 0.3 wt %, or from about 0.1 wt % to about 0.2 wt % of the total weight of the composition. Compositions of the invention may comprise one or more tight junction antagonists at a level of about 0.1 wt %, about 0.2 wt %, about 0.3 wt %, about 0.4 wt %, about 0.5 wt %, about 0.6 wt %, about 0.7 wt %, about 0.8 wt %, or about 0.9 wt % based on the total weight of the composition.

Compositions of the invention may comprise one or more tight junction antagonists at a level of from about 1 wt % to about 20 wt %, from about 1 wt % to about 18 wt %, from about 1 wt % to about 16 wt %, from about 1 wt % to about 14 wt %, from about 1 wt % to about 12 wt %, from about 1 wt % to about 10 wt %, from about 1 wt % to about 9 wt %, from about 1 wt % to about 8 wt %, from about 1 wt % to about 7 wt %, from about 1 wt % to about 6 wt %, from about 1 wt % to about 5 wt %, from about 1 wt % to about 4 wt %, from about 1 wt % to about 3 wt %, or from about 1 wt % to about 2 wt % of the total weight of the composition. Compositions of the invention may comprise one or more tight junction effectors at a level of about 1 wt %, about 2 wt %, about 3 wt %, about 4 wt %, about 5 wt %, about 6 wt %, about 7 wt %, about 8 wt %, or about 9 wt % based on the total weight of the composition.

The terms “stable in gastric fluid” or “stable in acidic environments” refers to a composition that releases 30% or less by weight of the total tight junction antagonist in the composition in gastric fluid with a pH of 5 or less, or simulated gastric fluid with a pH of 5 or less, in approximately sixty minutes. Compositions of the of the invention may release from about 0% to about 30%, from about 0% to about 25%, from about 0% to about 20%, from about 0% to about 15%, from about 0% to about 10%, 5% to about 30%, from about 5% to about 25%, from about 5% to about 20%, from about 5% to about 15%, from about 5% to about 10% by weight of the total tight junction antagonist in the composition in gastric fluid with a pH of 5, or less or simulated gastric fluid with a pH of or less, in approximately sixty minutes. As use herein, “about” used to modify a numerical value means within 10% of the value. Compositions of the invention may release about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight of the total tight junction antagonist in the composition in gastric fluid with a pH of 5 or less, or simulated gastric fluid with a pH of 5 or less, in approximately sixty minutes.

The term “unstable in intestinal fluid” refers to a composition that releases 70% or more by weight of the total tight junction antagonist in the composition in intestinal fluid or simulated intestinal fluid in approximately sixty minutes. The term “unstable in near neutral to alkaline environments” refers to a composition that releases 70% or more by weight of the total amount of tight junction antagonist in the composition in intestinal fluid with a pH of 5 or greater, or simulated intestinal fluid with a pH of 5 or greater, in approximately ninety minutes. For example, a composition that is unstable in near neutral or alkaline environments may release 70% or more by weight of a tight junction antagonist peptide in a fluid having a pH greater than about 5 (e.g., a fluid having a pH of from about 5 to about 14, from about 6 to about 14, from about 7 to about 14, from about 8 to about 14, from about 9 to about 14, from about 10 to about 14, or from about 11 to about 14) in from about 5 minutes to about 90 minutes, or from about 10 minutes to about 90 minutes, or from about 15 minutes to about 90 minutes, or from about 20 minutes to about 90 minutes, or from about 25 minutes to about 90 minutes, or from about 30 minutes to about 90 minutes, or from about 5 minutes to about 60 minutes, or from about 10 minutes to about 60 minutes, or from about 15 minutes to about 60 minutes, or from about 20 minutes to about 60 minutes, or from about 25 minutes to about 90 minutes, or from about 30 minutes to about 60 minutes.

In addition to a tight junction antagonist, compositions of the invention may further comprise one or more therapeutic agents. Therapeutic agents include, but are not limited to, steroids and other anti-inflammatory compounds. Suitable therapeutic agents may include one or more of aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologic therapies. Examples of suitable therapeutic agents that may be included in the compositions of the invention to treat IBD (e.g., Crohn's disease and/or ulcerative colitis) include, but are not limited to:

5-ASA agents (e.g., Sulfasalazine), Azulfidine®l, Asacol,® Dipentum,® Pentasa,® and Rowasa®;

Antibiotics, for example, metronidazole (Flagyl®) and ciprofloxacin (Cipro®), although there are many others that may be effective in certain individuals;

Steroids, e.g., corticosteroids. Suitable steroids include, but are not limited to, prednisone, hydrocortisone, Medrol®, and budesonide multiple-release capsule MRC (EntocortREC®).

6-mercaptopurine (6-MP, Purinethol®) and azathioprine (Imuran®); and

antibodies against inflammatory cytokines, e.g., Infliximab (Remicade™).

Compositions of the invention may also comprise one or more pharmaceutically acceptable excipients. Suitable excipients include, but are not limited to, buffers, buffer salts, bulking agents, salts, surface active agents, acids, bases, and binders.

Methods of Use

The compositions of the invention can be used for preventing, slowing the onset of, ameliorating and/or treating IBD (e.g., Crohn's disease and/or ulcerative colitis). In one embodiment, the present invention provides a method of treating Crohn's disease by administering a composition comprising one or more tight junction antagonists. In one embodiment, the present invention provides a method of treating ulcerative colitis by administering a composition comprising one or more tight junction antagonists.

In some embodiments, compositions of the invention may be given repeatedly over a protracted period, i.e., may be chronically administered. Typically, compositions may be administered one or more times each day in an amount suitable to prevent or reduce the likelihood of an attack of IBD (e.g., Crohn's disease and/or ulcerative colitis). Such compositions may be administered chronically, for example, one or more times daily over a plurality of days.

In some embodiments, compositions of the invention may be use to treat acute IBD (e.g., Crohn's disease and/or ulcerative colitis) attacks. Typically, embodiments of this type will require administration of the compositions of the invention to a subject undergoing an attack in an amount suitable to reduce the severity of the attack. One or more administration may be used.

EXAMPLES Effect of AT-1001 on Intestinal Permeability and Colitis in the IL-10 KO Mouse (129/Sve/IL-10KO)

The purpose of this study is to determine the ability of AT-1001, administered daily in drinking water to alter intestinal permeability (measured by absorption/excretion of lactulose and mannitol) and to inhibit the development of colitis in the 129/Svev/IL-10 KO mouse.

Anticipated* Suc/lac/Man/ #
Content Dose, Sucralose Animals
Animal AT-1001 (weight/ AT-1001 Dose (0.2 ml sugar per
Group ID's Treatment Formulation vehicle) mg/day probe gavage) Group
1 129/Svev/ Control 0 Sucrose 500 mg/ml 12
IL-10KO Lactulose 60 mg/ml
1M001-1M012 Mannitol 40 mg/ml
Sucralose 30 mg/ml
2 129/Svev/ Gavage of 0 Sucrose 500 mg/ml 12
IL-10KO probiotic Lactulose 60 mg/ml
2M001-2M012 conditioned Mannitol 40 mg/ml
media Sucralose 30 mg/ml
3 129/Svev/ Low dose of Neat AT-1001 0.2 Sucrose 500 mg/ml 12
IL-10KO AT-1001 Chemical in 0.1 mg/ml Lactulose 60 mg/ml
3M001-3M012 autoclaved, H2O Mannitol 40 mg/ml
H2O Sucralose 30 mg/ml
4 129/Svev/ High dose of Neat AT-1001 2 Sucrose 500 mg/ml 12
IL-10KO AT-1001 Chemical in 1 mg/ml Lactulose 60 mg/ml
4M001-4M012 autoclaved, H2O Mannitol 40 mg/ml
H2O Sucralose 30 mg/ml
5 129/Svev/ Control for 0 4
IL-10KO baseline
zonulin level
measurement
*assumes 2 ml/day water consumption

Dose Administration

Method and AT-1001 neat chemical in drinking water, and
Routes Suc/lac/man/sucralose given by gavage
Dosing Suc/lac/man/suralose: (Groups 1-4)
Timepoints 1. Weeks 1-2
Suc/lac/man/suralose solution on days 3, 6, and 9
2. Weeks 3-15
Suc/lac/man/suralose solution first day of every week
Probiotic conditioned media: (Group 2)
Daily in the mornings (Start Day 1 of study)
AT-1001 Neat Chemical 0.1 mg/ml: (Group 3)
Ad libidum (Start Day 1 of study)
AT-1001 Neat Chemical 1 mg/ml: (Group 4)
Ad libidum (Start Day 1 of study)
Duration Eighty days
Frequency AT-1001: continuously. Suc/lac/man/sucralose: Days 3,
6, 9, 14, 21, 28, 35, 41, 49, 56, 63, 70, 77, 84
Volume Suc/lac/man/sucralose 0.2 mL gavage per animal

Dose Administration Details

AT-1001 neat chemical will be administered ad libidum every day starting at day 1 to Group 3 at 0.1 mg/ml and Group 4 at 1 mg/ml in sterile water via the drinking water supply. Dosing of AT-1001 will be continued when the animals are in the metabolic cages for 22 hours. Probiotic conditioned medium will be given every morning to Group 2. The solution is prepared by dissolving 0.01 g in 10 ml of MRS medium and incubating it at 37° C. for 24 h. After incubation, the tube will be centrifuged 10 minutes at 10,000 rpm. The supernatant will be filtered through a 0.22 micron filter and diluted 1:10 with MRS medium. Animals will receive 30 μl of this dilution every morning. The conditioned media must be prepared fresh every morning. Sucrose/lactulose/mannitol/sucralose solution is prepared by dissolving Sucrose (50 mg), lactulose (6 mg), mannitol (4 mg), and sucralose (3 mg) in water (100 mL).

Each week, food and water will be removed 4 hours prior to gavage. All the collection vials will have 1001 of paraffin oil to avoid urine evaporation and 100 μl of thymol (10% m/w in propanol). Each animal will be gavaged with 0.2 ml of sugar solution, and placed in metabolic cages with access to H2O only for 22 hours. For the duration of the 22 hours, urine will be collected into previously weighed vials. At the end of the collection, the funnel of the cages will be washed off with 2 ml of water to collect any sugar that may have dried out before reaching the collection tube. After the collection of urine is complete, the animals will be placed in their respective cages, and provided with food and water. Each tube will be weighed to determine volume of urine collected. For the first 2 weeks, the animals will be handled, administered Suc/lac/man/suralose solution, and introduced to the cages 3 times during 10 days. After this it will be done once a week.

Test Articles

Test Articles

Identification Suc/lac/man/sucralose (Cat.# 84097, L7877,
#M9647, 7106A respectively)
Lot/Batch Number New sucrose has not arrived yet, 1085532, 036935,
011B99, respectively
Purity, Maintained by manufacturer
Composition,
and Expiry
Storage Conditions Room temperature
Source and Sigma Chemical Corporation, St. Louis, MO
Manufacturer
Special Handling Appropriate PPE required (Lab coat, safety glasses,
Precautions gloves).
Prepared Immediately prior to dosing

Identification AT1001 (neat chemical, Groups 3, and 4)
Lot/Batch Number AT1001; Lot E050082
Purity and >95%; neat AT1001
Composition
Storage Conditions Frozen
Source and Solvay/Peptisyntha Inc
Manufacturer
Special Handling Appropriate PPE required (Lab coat,
Precautions safety glasses, and gloves)
Prepared Freshly prepared each day prior to dosing

Identification Probiotic conditioned media
Lot/Batch Number 5160D5
Storage conditions Room temperature
Source and manufacturer Sigma-Tau Pharmaceuticals
Special Handling Precautions Use aseptic technique and
appropriate PPE required (Lab
coat, safety glasses, gloves).
Prepared Dissolve 0.1 g in 10 ml of MRS
media, incubate at 37 C for 24
hours. Filter through 0.22 μm
membrane and dilute filtrate
1/10 in MRS media. Gavage
animals with 30 μl.

Preparation of Test Articles

Test Article Suc/lac/man/suralose AT1001 AT1001
solution (neat chemical) (neat chemical)
(Groups 1, 2, 3, and 4) (Group 3) (Group 4)
Type of Solution in water Oral solution in Oral solution in
Formulation drinking water drinking water
Method of Weigh 50 g of sucrose, 6 g Weigh 10 mg of neat Weigh 100 mg of
Preparation of lactulose, 4 g of AT1001. Dissolve in neat AT1001.
mannitol and 3 g of 100 mL sterile water. Dissolve in 100 mL
sucralose and dissolve in sterile water.
100 ml of sterile water.
Frequency of Every week Every day Every day
Preparation
Dose Sucrose 500 mg/ml 0.1 mg/ml 1 mg/ml
Concentration Lactulose 60 mg/ml
Mannitol 40 mg/ml
Sucralose 30 mg/ml
Dose Volume 0.2 ml N/A N/A
Storage Refrigerated Refrigerated Refrigerated
Conditions

Test System

Species/Strain or Breed 129/Svev/IL-10 KO mouse
Age at Study Initiation Approximately 28 days
Weight Approximately 10 grams at study initiation and
20 grams at study termination
Acclimation At least 3 days
Selection Criteria/ Randomized assignment of group and animal
Randomization number prior to study start
Identification Ear markings and cage cards
Animal Use Protocol 138
Number

Animals to be used on this study will be selected on the basis of acceptable findings from physical examination and body weights. The animals will then be assigned to treatment groups prior to dosing.

Environmental Conditions

Caging Individually housed cages and in metabolism cages during
urine collection
Bedding Direct bedding - 3 wood chips prior to study start
Temperature Approximate range 72 +/− 4° F.
Humidity Range 30% to 70%
Lighting Approximate 12-hour light, 12-hour dark cycle. The
lighting cycle may be interrupted for performance of
protocol-defined activities.
Water Sterile filtered (0.22 micron filter) water
Diet Certified Purina Rodent Meal 5001.

Clinical And Physical Examinations

Survival and Throughout treatment periods of study
Moribundity
Observations
Clinical Signs Once daily
Unscheduled To be performed at the discretion of the study
Observations director/principal investigator
Physical Examinations To be conducted once prior to the initiation of
dosing
Routine Body Weights Prior to randomization and the first day of
every week thereafter
Food Consumption Two times a week. Mice will be fasted 4 hours
prior to each sugar gavage
Water Consumption Every day.
Stool Collection First day of every week and screened for the
presence of blood

Clinical Pathology

Urine Collection

During each intestinal permeability trial, all subjects will be gavaged with suc/lac/man/sucralose solution and placed in metabolic cages immediately after to enable urine collection. Urine from each animal will be collected for 22 hours in chilled collection tubes, treated with 100 μL of a 10% Thymol solution (1.0 g/10 mL isopropanol) and paraffin oil (100 μL, to prevent urine evaporation) from the following interval post dosing 24 hours. Samples will be frozen at −80° C. until analysis. All sugars will be quantified by ion exchange HPLC. LAMA ratio, total sucrose and total sucralose will be obtained per measurement.

Stool Sample Collection

On the first day of every week stool sample will be collected from every animal and screened for the presence of blood. Stool samples will also be collected at the termination of the study.

Sample Storage Conditions

50-100 μl serum from animals in Group 5 will be frozen until zonulin measurements made. 100 μl serum from animals from Groups 1-4 at Day 57 and at day 77 will be frozen at −20° C. until zonulin measurements made.

Sacrifice Schedule

Animals found dead will be refrigerated and necropsied at the earliest possible time (within working hours). Terminal body weight organ weights will not be taken from animals found dead. Protocol defined tissues will be collected.

Moribund/unscheduled animals that are sacrificed during normal working hours will be taken immediately to necropsy. A terminal body weight will be taken and the animal will be necropsied. Protocol defined tissues for histology will be taken. Moribund/unscheduled sacrifice animals that are sacrificed outside of normal working hours will be refrigerated after a terminal body weight and necropsied at the earliest possible time (within working hours). Organ weights will not be collected unless the entire study is sacrificed early and control organ weights can be collected at the same time or the study is taken down at the scheduled sacrifice.

Animals Found Dead Animals found dead will be refrigerated and
necropsied at the earliest possible time (within
working hours). Gross findings will be noted.
Moribund/Unscheduled Sacrifice Moribund/unscheduled sacrifice animals that are
sacrificed outside of normal working hours will be
refrigerated and necropsied at the earliest possible
time (within working hours). Gross findings will be
noted. Protocol-defined tissues will be collected.
Sacrifice Schedule 1.At time 0, all 4 animals of group 5 will be
sacrificed. 50-100 μl serum will also be collected to
measure zonulin levels.
2. After 8 weeks, on day 57, 4 animals from the
Groups 1-4 will be sacrificed and their intestinal
permeability (small bowel and colon) will be
measured using Ussing chambers and samples
from both sites will be assessed for histology, MPO
and cytokine secretion. 100 μl of serum will be
collected from these animals and sent to Alba
Therapeutics for zonulin levels determination.
3. On day 77, after final urine collection, all animals
will be sacrificed for measurements as above.
Number of Animals All
(survival permitting)
Method of Euthanasia Cervical dislocation
Fasting Requirements Animals will be fasted overnight prior to necropsy
Terminal Body Weight Will be taken at necropsy
Macroscopic Examination Will be performed by the study pathologist at necropsy

Immediately upon expiration, stomachs, small intestines, and colons will be collected and weighed. Each tissue will be scored for macroscopic lesions to assess intestinal damage by the Study Pathologist. ELISAs will be performed on each tissue to measure the levels of MPO, IL-8, TNFα, and IFNγ. A section of the tissues will be fixed in formalin for HE histology. The day after the final intestinal permeability measures on day 77, all surviving animals will be euthanized and intestinal tissues collected and processed.

Clinical observations, physical examinations, and body weights will be recorded on appropriate paper forms. Sucrose, lactulose, mannitol, and sucralose and lactulose:mannitol ratios will be determined according to the published procedures.

Data Acquisition

The following data will be acquired

Data Type Schedule
Weights 1. Weigh all animals on the first day of every week
2. Weigh all animals at sacrifice
3. Week 8
Sacrifice 4 animals from each group to dissect out stomachs, small
intestines,
and colons and weigh them
4. Week 11
Sacrifice the remaining 8 animals from each group to dissect out
stomachs,
and intestines, and colons and weigh them
Suc/lac/manLAMA 1. Weeks 1-2
in urine Administer Suc/lac/man/suralose and collect urine for 22 hours on
days 3, 6, 9
2. Weeks 3-11
Administer Suc/lac/man/suralose and collect urine urine for 22 hours
on days 14, 21, 28, 35, 41, 49, 56, 63, 70, 77
Intestinal 1. Week 8 - Day 57 of study
permeability with Sacrifice 4 animals from each group to dissect out stomachs, small
Ussing chambers intestines
and colons and measure intestinal permeability
2. Week 11 - termination of study at day 77
Sacrifice the remaining 8 animals from each group to dissect out
stomachs, small intestines and colons and measure intestinal
permeability
Scoring lesions 1. Day 1
histologically Dissect out stomachs, small intestines and colons of 4 animals in
Group 5 for
scoring macroscopic lesions as control, fix sections for histology.
2. Week 8 - Day 57 of study
Dissect out stomachs, small intestines and colons of 4 animals from
Groups
1-4 for scoring macroscopic lesions, fix sections for histology
3. Week 11 - Day 77 of study
Dissect out stomachs, small intestines and colons of remaining 8
animals from Groups 1-4 for scoring macroscopic lesions, fix sections
for histology
Zonulin levels 1. Sacrifice all 4 animals from Group 5 to measure zonulin levels day 1
2. Week 8 - Day 57 of study
Measure zonulin levels in the animals from Groups 1-4 sacrificed
on this day
2. Week 11- Day 77 of study
Measure zonulin levels in the animals from Groups 1-4 sacrificed on
this day
Levels of MPO, 1. Measure levels of these proteins in animals from Group 5
IL-8, TNF-α, IFNγ 2. Measure levels of these proteins in animals from Groups 1-4 at the
beginning of Week 8 - Day 57 of study
3. Measure levels of these proteins in animals from Groups 1-4 when
study is terminated at Week 11 - Day 77 of study
Water 1. Measure water consumption daily for dose measurement
consumption

FIGS. 1-4 show that development of disease is associated with an increase in small intestinal permeability. This increase can be abrogated by high dose AT-1001.

FIG. 5-10 show the results of analysis of disease in the colon. Disease in the colon was evaluated at both 8 and 17 week time points. The former with Ussing chamber measurements and the latter with histology, mucosal cytokine secretion, MPO and sucralose permeability. At 8 weeks of age AT-1001 reduced colonic permeability to mannitol and prevented the reduction in electrical resistance observed in the untreated animals. At 17 weeks AT-1001 reduced all tissue markers of colonic inflammation that were measured

All publications, patents and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8034776Oct 26, 2007Oct 11, 2011Alba Therapeutics CorporationOrallyl administering a zonulin antagonist comprising an octapeptide; monitoring; administering a gluten challenge; diagnosis of celiac disease by determining amount of interferons, interleukins, or nitrates in a sample and evaluating
US8168594Nov 11, 2009May 1, 2012Alba Therapeutics CorporationMethod for treating celiac disease
US8299017May 27, 2010Oct 30, 2012Alba Therapeutics Corp.Use of tight junction antagonists to treat inflammatory bowl disease
Classifications
U.S. Classification514/1.1
International ClassificationA61K38/00, A61P1/00
Cooperative ClassificationA61K38/08, C07K7/06
European ClassificationA61K38/08
Legal Events
DateCodeEventDescription
Oct 9, 2008ASAssignment
Owner name: ALBA THERAPEUTICS CORPORATION, MARYLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PATERSON, BLAKE;TAMIZ, AMIR;PANDEY, NIRANJAN;REEL/FRAME:021656/0350
Effective date: 20080620